Genetic Technologies

Genetic Technologies Ltd. is a molecular diagnostics company, which engages in the provision of molecular risk assessment tests for cancer. It operates through EasyDNA and GeneType/Corporate segments. The EasyDNA segment focuses on EasyDNA branded test sales and expenses. The GeneType/Corporate segment includes tha GeneType branded test sales and expenses, including corporate charges. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.

Earnings data Q1 2024

Genetic Technologies Ltd. engages in the provision of molecular risk assessment tests for cancer. It operates through the following segments: EasyDNA, AffinityDNA, and GeneType/Corporate. The EasyDNA segment focuses on EasyDNA branded test sales and expenses. The AffinityDNA segment deals with AffinityDNA branded test sales and expenses. The GeneType/Corporate segment includes the GeneType branded test sales and expenses, including corporate charges. The company was founded on January 5, 1987, and is headquartered in Fitzroy, Australia.

Genetic Technologies Limited (NASDAQ:GENE ) Q3 2022 Earnings Conference Call April 20, 2022 6:00 PM ET Company Participants Simon Morriss – Chief Executive Officer Mike Tonroe – Chief Financial Officer Dr. George Muchnik – Non-Executive Director and Medical Advisor Conference Call Participants MichaelTonroe Hello and welcome to our Quarter Three business update. I'm Mike Tonroe, Chief Financial Officer Genetic Technologies.

Genetic Technologies Limited (GENE) CEO Simon Morriss on Q3 2022 Results - Earnings Call Transcript

MELBOURNE, Australia, April 08, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, ASX: GTG) (“GENE” or the “Company”), a global leader in genomics-based tests in health, wellness and serious disease provides its year to date results for the nine months ended March 31, 2022.

Genetic Technologies drives leadership in precision medicine with Multi-Risk Test

Applied Genetic Technologies

Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q2 2022 Results - Earnings Call Transcript

Q2 momentum sets the stage for a strong FY22 Q2 momentum sets the stage for a strong FY22

Genetic Technologies Reports Q2 FY22 Cash Flow Results

MELBOURNE, Australia, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease confirms that the Company's Director of Clinical Affairs & Medical Education, Erika Spaeth, PhD will be presenting at 2021 San Antonio Breast Cancer Symposium.

GENE Presents Study Involving 200,000 Participants at 2021 San Antonio Breast Cancer Symposium

MELBOURNE, Australia, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease confirms that the Company's US patent application for its novel geneType COVID-19 Risk Test has been accepted:

Genetic Technologies Announces New Partnership and geneType COVID-19 Risk Test Patent Allowance from the USPTO

Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q1 Fiscal Year 2022 Results - Earnings Call Transcript

Genetype MultiTest submitted for regulatory approval as commercialization plans gather momentum increase in cash receipts over prior quarter Genetype MultiTest submitted for regulatory approval as commercialization plans gather momentum increase in cash receipts over prior quarter

Genetic Technologies Reports Q1 FY22 Results

Study to focus on women of African American descent for expanded polygenic risk test Study to focus on women of African American descent for expanded polygenic risk test

GENE Embarks on Breakthrough African American Collaboration for Breast Cancer as Part of Its Commitment to Ethnic Diversity

Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q4 2021 Results - Earnings Call Transcript

FORT LAUDERDALE, Fla., Sept. 9, 2021 /PRNewswire/ -- September 9, 2021–BelHealth Investment Partners, LLC ("BelHealth") is pleased to announce that it has completed the sale of assets of the international division of General Genetics Corporation (GGC), a provider of relationship and clinical genetic testing services, to Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company ("GTG").

BelHealth Completes Asset Sale of General Genetics Corp.

Company to present at H.C. Wainwright 23rd Annual Global Investment Conference taking place virtually September 13-15, 2021 Company to present at H.C. Wainwright 23rd Annual Global Investment Conference taking place virtually September 13-15, 2021

Genetic Technologies Reports FY21 Results as it Turns the Corner on its Commercialization Strategy

MELBOURNE, Australia, July 26, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”, “GTG”), a global leader in Genomics based tests in health, wellness and serious disease, is pleased to provide its Quarterly Business Update to the market.

Genetic Technologies Rapidly Accelerating Commercialization Plans

Genetic Technologies Limited (NASDAQ: GENE) has agreed to acquire EasyDNA's brand and distribution rights from BelHealth for $4 million in cash and stock. EasyDNA currently sells paternity, oncology, and health & wellness genomics-based laboratory tests through agreements with 12 laboratories in North America, AsiaPac, and Europe.

Genetic Technologies Acquires EasyDNA To Expand Into Wellness Testing

A global platform to market the Company's portfolio across 40 countries A global platform to market the Company's portfolio across 40 countries

Genetic Technologies Strengthens Global Leadership in Genomics with Acquisition of EasyDNA

MELBOURNE, Australia, July 09, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG, NASDAQ: GENE, "Company", "GTG"), a diversified Genomics and AI driven preventative health business, today announced updates on the development of its Predictive Panel Risk Test designed to cover six different cancers including breast and colorectal cancer, prostate and ovarian cancer, pancreatic cancer and melanoma.

Genetic Technologies Continues to Break New Ground as it Advances Development of its Predictive Risk Test for Multiple Cancers & Morbidities

MELBOURNE, Australia, June 11, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI driven preventative health business, has been granted US Patent No. 11,031,098 – ‘Computer Systems and Methods for Genomic Analysis'.

US Patent Office Grants Foundational Pharmacogenomic Patent

PISCATAWAY, N.J.--(BUSINESS WIRE)-- #covid19--Today, Infinity BiologiX (IBX) announces the launch of a new test meant to assess the severity of COVID-19 in individuals. The COVID-19 Risk Test is designed to predict disease severity in people ages 18 and older, using genetic and clinical information to provide a risk score - individuals can then use that score to understand their personal risk of contracting a serious case of COVID-19 and make more informed decisions. In addition, employers, governments, a

Infinity BiologiX, Genetic Technologies and Vault Heath launch new test to assess severity of COVID-19 in individuals

MELBOURNE, Australia, May 13, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI driven preventative health business, today announced an interview with Simon Morriss, CEO, will air on The RedChip Money Report® on the Bloomberg Network in the U.S. on Saturday, May 15th, at 7 p.m. local time in 73M homes across the United States.

Genetic Technologies Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®

Genetic Technologies Ltd. is moving closer to potential approval of distribution of its COVID-19 Risk Test in the U.S.

Genetic Technologies Ltd. Will Jump If Its Predictive Tests Are Approved

MELBOURNE, Australia, April 12, 2021 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), announces the appointment of Michael Tonroe to the role of Chief Financial Officer, commencing on 28 June 2021.

Genetic Technologies appoints Mike Tonroe as CFO

MELBOURNE, Australia, April 09, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI driven preventative health business provides an update to the market on the progress of the US commercial availability of the Company's COVID-19 Serious Disease Risk (“COVID-19 Risk Test”) via US Based Infinity BiologiX LLC (‘IBX'), (ref: ASX Announcement 3 March 2021).

Genetic Technologies Provides Update on COVID-19 Risk Test Launch

The stock price of Genetic Technologies Limited (NASDAQ: GENE) is trading at above 25% pre-market. This is why it happened.

GENE Stock Price Increases Over 25% Pre-Market: Why It Happened

MELBOURNE, Australia, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, today announced an interview with Dr. George Muchnicki, Chief Medical Officer and Executive Director, will air on The RedChip Money Report® on Bloomberg TV in the US on Saturday, February 27, at 7 p.m. local time in 73M homes across the United States. The RedChip Money Report® also airs on Bloomberg International in Europe in 100M homes at 6 pm local time on Sundays.

Genetic Technologies Limited Interview to Air on Bloomberg TV in the US on the RedChip Money Report®

Genetic Technologies Limited (GENE) Acting CEO George Muchnicki on Quarterly Investor Webinar Transcript

News for Genetic Technologies Stock (GENE)